{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T08:10:36Z","timestamp":1698048636796},"reference-count":19,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,8,7]],"date-time":"2009-08-07T00:00:00Z","timestamp":1249603200000},"content-version":"vor","delay-in-days":7433,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[1989,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>AR\u2010C 239 is a new specific alpha<jats:sub>1<\/jats:sub> antagonist drug with an action similar to that of prazosin. In dogs it appears to be specific for the alpha<jats:sub>1<\/jats:sub> adrenoreceptor. AR\u2010C 239 was tested in 11 patients (49 \u00b1 11 years old) with left heart failure, who had not received any previous treatment. The drug was infused intravenously with a stepwise increase in dose, producing three stable plasma concentration plateaus: 10 \u00b1 2, 51 \u00b1 3, and 138 \u00b1 55 ng\/ml. Hemodynamic data were collected at time T0 before drug infusion, and half\u2010way through each infusion. Blood pressures and cardiac output were recorded using a Millar microtip manometer (left ventricle), a Swan\u2010Ganz catheter (pulmonary artery), and a femoral catheter, connected to a Syscomoram computer system which calculated the following parameters: work, resistances, tension\u2014time index and contractility indices. Left ventricular ejection fraction and volumes were obtained from cineangiograms performed 30 min before drug infusion and at the end of the third infusion plateau. AR\u2010C 239 produces a dose\u2010dependent fall in systemic blood pressure (r=0.539, n=33, p&lt;.001). Maximal beneficial effects are reached with the second infusion dose with a dramatic fall in systemic (peripheral) resistance (\u221230\u00b121%, p\u00b10.01), accompained by a decrease in pulmonary resistance (\u221222\u00b124%, p&lt;.05), leading to a drop in the tension\u2010time index (\u221222\u00b116%, p&lt;.01), a fall in LV filling pressure (\u221217\u00b18%, p&lt;.001), and an improvement in cardiac index (+20\u00b118%, p&lt;.02). Apart from a reflex\u2010related increase in heart rate (14\u00b110%, p&lt;.01), the drug does not affect contractility indices such as extrapolated Vmax. No adverse reactions were noted during the experiment. AR\u2010C 239 appears to be a powerful vasodilator via selective alpha<jats:sub>1<\/jats:sub>\u2010adrenoreceptor blockade. Its good tolerance together with the large range of available dose concentrations indicate that this drug could be useful in the acute management of left heart failure.<\/jats:p>","DOI":"10.1002\/clc.4960120407","type":"journal-article","created":{"date-parts":[[2009,8,8]],"date-time":"2009-08-08T09:24:07Z","timestamp":1249723447000},"page":"215-220","source":"Crossref","is-referenced-by-count":0,"title":["Hemodynamic effects of continuous infusion of AR\u2010C 239 in left ventricular failure"],"prefix":"10.1002","volume":"12","author":[{"given":"J. P.","family":"Colle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Besse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,8,7]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198003000-00009"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(81)90190-4"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1358\/dof.1981.006.02.1003960"},{"issue":"1","key":"e_1_2_1_5_2","first-page":"25","article-title":"Hemodynamic effects of intravenous administration of a new alpha1 antagonist drug AR\u2010C 239 in patients with left heart failure (abstr)","volume":"6","author":"Colle JP","year":"1985","journal-title":"Eur Heart J"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(81)90218-0"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.31.2.154"},{"key":"e_1_2_1_8_2","first-page":"719","article-title":"Phentolamine for vasodilator treatment of severe heart failure","volume":"2","author":"Majid PA","year":"1981","journal-title":"Lancet"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/000331977903000708"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.76.5.571"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.58.1.157"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(70)90826-X"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198006193022504"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(70)90542-4"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00998579"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.56.3.346"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(78)90703-9"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.42.6.657"},{"key":"e_1_2_1_19_2","first-page":"1","article-title":"Positive intropic hydralazin in human subjects comparison with praz setting of congestive heart failure","volume":"46","author":"Leier CV","journal-title":"Am J Cardiol"},{"key":"e_1_2_1_20_2","article-title":"Sustained recardiac impedance and preload in congestive heart the antihypertensive vasodilator prazosin","volume":"303","author":"Miller RR","year":"1977","journal-title":"N Engl."}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.4960120407","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.4960120407","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T13:17:56Z","timestamp":1697980676000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.4960120407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1989,4]]}},"alternative-id":["10.1002\/clc.4960120407"],"URL":"https:\/\/doi.org\/10.1002\/clc.4960120407","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[1989,4]]}}}